Clinical Trial Update: Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection [Phase 1]

View source ↗

Summary

Phase 1 trial update showing safety, tolerability, and pharmacokinetics of escalating doses of VCH 916 in subjects with hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• VCH 916

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: HCV Infection | Phase 1 | Status: COMPLETED